Skip to content
AnalystLens

Merck Annual Report, Year Ended Dec 31, 2011

Filing Date
Filed February 28, 2012
Period End
December 31, 2011
Security
MRK
In the record · 2016–202610-K1210-Q338-K87

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 87 current reports (8-K) between 2016 and 2026.

  1. Impairment8-K · Feb ’17Feb ’17
  2. Restructuring8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Aug ’21Aug ’21
  4. Restructuring8-K · Jul ’25Jul ’25

Summary

Summary of the 10-K filed February 28, 2012. Cited figures are marked; the original filing is the authoritative source.

Merck & Co., Inc. reported strong sales growth of 4% to $48.0 billiona for the fiscal year ended December 31, 2011, driven by key products like Januvia, Janumet, and Singulair, along with contributions from their Animal Health division and the launch of Victrelis.

The company continued its strategic focus on accelerating revenue growth and cost efficiencies through its Merger Restructuring Program, which is on track to deliver substantial savings. Despite facing patent expirations for some products and the ongoing impact of healthcare reforms and European austerity measures, Merck demonstrated resilience. The company also advanced its research and development pipeline, with several new drug candidates under regulatory review and in late-stage development, signaling a commitment to future growth.

Key Highlights

  1. Merck reported a 4% increase in worldwide sales, reaching $48.0 billion in 2011, primarily driven by strong performance in diabetes treatments (Januvia, Janumet), Singulair, and Gardasil.
  2. The company continued its global restructuring program aimed at optimizing costs, having realized approximately $2.9 billion in annual net cost savings since the merger and expecting further savings.
  3. Merck's R&D pipeline showed progress with 19 drug candidates in Phase III development, and plans to file for approval of five major products between 2012 and 2013.
  4. Healthcare reform in the U.S. impacted revenues through increased Medicaid rebates and the Medicare Part D coverage gap discount, totaling approximately $329 million.
  5. European austerity measures and pricing actions negatively affected sales in the EU, a trend Merck anticipates will continue.
  6. The company announced a quarterly dividend increase to $0.42 per share, reflecting confidence in its financial position.
  7. Key products like Singulair and Maxalt are nearing patent expiration, with significant sales declines expected post-expiration, highlighting the importance of the R&D pipeline.

Financial Statements

FY2011 against FY2010

Line itemFY2011FY2010Change
Revenue$48.05B$45.99B+4.5%
Cost of Revenue$16.87B$18.40B−8.3%
Gross Profit$31.18B$27.59B+13.0%
R&D Expenses$8.47B$11.11B−23.8%
SG&A Expenses$13.73B$13.13B+4.6%
Interest Expense$695.00M$715.00M−2.8%
Net Income$6.27B$861.00M+628.5%
EPS (Basic)$2.04$0.28+628.6%
EPS (Diluted)$2.02$0.28+621.4%
Shares Outstanding (Basic)3.07B3K+99224455.7%
Shares Outstanding (Diluted)3.09B3K+99166566.7%

Frequently Asked Questions

  1. What was Merck's overall financial performance in 2011?

    Merck reported a 4% increase in worldwide sales, reaching $48.0 billion in 2011, driven by strong performance in several key pharmaceutical and vaccine products. Earnings per share were $2.02, which included impacts from acquisition-related costs, restructuring, and other charges.

  2. What are the main growth drivers for Merck's sales?

    Growth drivers included strong performance from diabetes treatments Januvia and Janumet, the respiratory medicine Singulair, the HPV vaccine Gardasil, and the HIV treatment Isentress. Additionally, the Animal Health segment and the launch of Victrelis for hepatitis C contributed to the revenue increase.

  3. What are the significant risks and challenges facing Merck?

    Key risks include the upcoming patent expirations for major products like Singulair and Maxalt, which are expected to lead to significant sales declines. Other challenges include pricing pressures globally, increased competition from generics, the impact of U.S. healthcare reform, European austerity measures, and ongoing litigation, particularly related to Vioxx.

  4. How is Merck managing its cost structure and future growth?

    Merck is actively managing its cost structure through its Merger Restructuring Program, aiming for substantial annual cost savings. Future growth is being driven by advancements in its R&D pipeline, with numerous drug candidates in late-stage development and strategic acquisitions, such as Inspire Pharmaceuticals.